基质金属蛋白酶-9作为 HER-2 富集型乳腺癌治疗的预后因素。

Matrix Metalloproteinase-9 as Prognostic Factor for the Treatment of HER-2 Enriched Breast Cancer.

机构信息

Surgical Oncology at Dr. M. Djamil General Hospital/ Faculty of Medicine Universitas Andalas, Padang-Indonesia.

Trainee of Surgical Oncology at Dr. M. Djamil General Hospital/ Faculty of Medicine Universitas Andalas, Padang-Indonesia.

出版信息

Asian Pac J Cancer Prev. 2022 Mar 1;23(3):1013-1021. doi: 10.31557/APJCP.2022.23.3.1013.

DOI:10.31557/APJCP.2022.23.3.1013

PMID:35345375

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9360959/

Abstract

BACKGROUND

MMP-9 plays a significant role in invasion and migration of tumor cells and metastasis. A combination MMP-9 biomarker with HER2 and Ki-67 is expected to provide more specificity in prognosis for better breast cancer (BC) treatment options.

METHODS

A retrospective cohort of 34 patients with HER2 enriched breast cancer were studied from January 2016 until December 2020. Assessment MMP-9 by IHC using Monoclonal Mouse Anti-Human MMP-9 Antigen with semiquantitative immunoreactive scores methods was done.

RESULTS

The samples included patients aged 29 to 66 years. Patients' educational level was mostly high school graduation (n=17; 50%). Distant metastases occurred in 10 (29.4%) patients, histopathological Grade II was found in 29 (85.7%) patients, positive LVI was found in 18 (52.9%) patients, and high proliferation rate (Ki67 > 20%) was found in 32 (94.1%) patients. All the patients underwent MRM with a history of chemotherapy in 29 (85.3%) patients, radiotherapy in 14 (41.2%) patients, and targeted therapy in only seven (20.6%) patients. Most of the patients had locally advanced stage III (n=21; 61.8%). The MMP-9 High expression was found in 20 (58.8%) patients and 14 (41.2%) patients had a low expression. A significant relationship was found between MMP-9 expression and DFS (p=0.023); while a significant relationship was found with OS (p=0.093). The mean DFS for High expression MMP-9 was 37.3 months and 45.3 months for low expression. The mean OS was 37.6 months for High-intensity MMP-9 and 42.7 months for Low-intensity.

CONCLUSIONS

The MMP-9 expression (p=0.037), age group<40 years old (p=0.024), and the history of radiotherapy (p=0.035) were significantly related to he occurrence of distant metastases. The MMP-9 High expression had a 7.5 times greater risk of distant metastases.

IMPACTS

The MMP-9 can be used as a prognostic factor for distant metastasis in HER2 Enriched BC.

摘要

背景

MMP-9 在肿瘤细胞的侵袭和迁移以及转移中起重要作用。与 HER2 和 Ki-67 联合的 MMP-9 生物标志物有望在预后方面提供更高的特异性，从而为更好的乳腺癌（BC）治疗选择提供更多信息。

方法

对 2016 年 1 月至 2020 年 12 月期间的 34 例 HER2 富集型乳腺癌患者进行回顾性队列研究。使用单克隆小鼠抗人 MMP-9 抗原通过半定量免疫反应性评分方法进行 MMP-9 的免疫组织化学评估。

结果

纳入的患者年龄为 29 至 66 岁。患者的教育水平主要为高中毕业（n=17；50%）。10 例（29.4%）患者发生远处转移，29 例（85.7%）患者组织学分级为 II 级，18 例（52.9%）患者发现淋巴血管侵犯阳性，32 例（94.1%）患者Ki67 增殖率高（>20%）。所有患者均接受了 MRM 检查，其中 29 例（85.3%）患者有化疗史，14 例（41.2%）患者有放疗史，仅有 7 例（20.6%）患者有靶向治疗史。大多数患者为局部晚期 III 期（n=21；61.8%）。MMP-9 高表达者 20 例（58.8%），低表达者 14 例（41.2%）。MMP-9 表达与 DFS（p=0.023）之间存在显著相关性，与 OS（p=0.093）之间存在显著相关性。高表达 MMP-9 的中位 DFS 为 37.3 个月，低表达 MMP-9 的中位 DFS 为 45.3 个月。高表达 MMP-9 的中位 OS 为 37.6 个月，低表达 MMP-9 的中位 OS 为 42.7 个月。